Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors-Reference-Cited by-同舟云学术

Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors

Published:2024-04-29 Issue:4 Volume:74 Page:359-367
ISSN:0007-9235
Container-title:CA: A Cancer Journal for Clinicians
language:en
Short-container-title:CA A Cancer J Clinicians

Author:

Chauhan Aman¹,Chan Kelley²,Halfdanarson Thorvardur R.³,Bellizzi Andrew M.⁴,Rindi Guido⁵⁶,O’Toole Dermot⁷,Ge Phillip S.⁸,Jain Dhanpat⁹,Dasari Arvind¹⁰,Anaya Daniel A.¹¹,Bergsland Emily¹²,Mittra Erik¹³,Wei Alice C.¹⁴,Hope Thomas A.¹⁵,Kendi Ayse T.¹⁶,Thomas Samantha M.¹⁷,Flem Sherlonda¹⁸,Brierley James¹⁹,Asare Elliot A.²⁰^ORCID,Washington Kay²¹,Shi Chanjuan²²^ORCID

Affiliation:

1. Department of Medicine Neuroendocrine Oncology Sylvester Comprehensive Cancer Center University of Miami Health System Miami Florida USA

2. Department of Surgery Loyola University Medical Center Chicago Illinois USA

3. Division of Medical Oncology Department of Oncology Mayo Clinic Rochester Minnesota USA

4. Department of Pathology University of Iowa Carver College of Medicine Iowa City Iowa USA

5. Department of Life Sciences Section of Anatomic Pathology Università Cattolica del Sacro Cuore Rome Italy

6. Department of Woman and Child Health Sciences and Public Health Anatomic Pathology Unit Fondazione Policlinico Universitario A. Gemelli IRCCS and Roma‐Gemelli European Neuroendocrine Tumor Society Center of Excellence Rome Italy

7. National Center for Neuroendocrine Tumors, European Neuroendocrine Tumor Society Center of Excellence (St Vincent’s University Hospital) and St James Hospital Trinity College Dublin Dublin Ireland

8. Department of Gastroenterology, Hepatology and Nutrition The University of Texas MD Anderson Cancer Center Houston Texas USA

9. Department of Pathology Yale School of Medicine New Haven Connecticut USA

10. Department of Gastrointestinal Medical Oncology Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston Texas USA

11. Department of Gastrointestinal Oncology‐Surgery Moffitt Cancer Center Tampa Florida USA

12. Department of Medicine University of California San Francisco San Francisco California USA

13. Department of Diagnostic Radiology, Molecular Imaging and Therapy Oregon Health and Science University Portland Oregon USA

14. Department of Surgery Memorial Sloan Kettering Cancer Center New York New York USA

15. Department of Radiology University of California San Francisco San Francisco California USA

16. Department of Radiology Mayo Clinic Rochester Minnesota USA

17. Department of Biostatistics and Bioinformatics Duke University School of Medicine Durham North Carolina USA

18. Tumor Registrar The University of Texas MD Anderson Cancer Center Houston Texas USA

19. Radiation Medicine Program Princess Margaret Cancer Center University of Toronto Toronto Ontario Canada

20. Department of Surgery University of Utah Salt Lake City Utah USA

21. Department of Pathology, Microbiology and Immunology Vanderbilt University Medical Center Nashville Tennessee USA

22. Department of Pathology Duke University Medical Center Durham North Carolina USA

Abstract

AbstractThe American Joint Committee on Cancer (AJCC) staging system for all cancer sites, including gastroenteropancreatic neuroendocrine tumors (GEP‐NETs), is meant to be dynamic, requiring periodic updates to optimize AJCC staging definitions. This entails the collaboration of experts charged with evaluating new evidence that supports changes to each staging system. GEP‐NETs are the second most prevalent neoplasm of gastrointestinal origin after colorectal cancer. Since publication of the AJCC eighth edition, the World Health Organization has updated the classification and separates grade 3 GEP‐NETs from poorly differentiated neuroendocrine carcinoma. In addition, because of major advancements in diagnostic and therapeutic technologies for GEP‐NETs, AJCC version 9 advocates against the use of serum chromogranin A for the diagnosis and monitoring of GEP‐NETs. Furthermore, AJCC version 9 recognizes the increasing role of endoscopy and endoscopic resection in the diagnosis and management of NETs, particularly in the stomach, duodenum, and colorectum. Finally, T1NXM0 has been added to stage I in these disease sites as well as in the appendix.

Publisher

Wiley

Reference57 articles.

1. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States

2. Neuroendocrine Tumors—Less Well Known, Often Misunderstood, and Rapidly Growing in Incidence

3. Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline

4. Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Isolated Tumor Cells Node Micro-metastasis in Early-Stage Small Intestinal Neuroendocrine Tumor;Endocrine Pathology;2024-08-22

2. Pathological Features Associated with Lymph Node Disease in Patients with Appendiceal Neuroendocrine Tumors;Cancers;2024-08-22

3. AJCC Cancer Staging System Version 9: Practice-Informing Updates for Gastroenteropancreatic Neuroendocrine Tumors;Annals of Surgical Oncology;2024-06-13